You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR RABEPRAZOLE SODIUM


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Rabeprazole Sodium

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT01286194 ↗ A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms Completed Eisai Inc. 2006-04-01 This is a multi-center, open-label, all-comers OTC actual use study in pharmacy sites where the principal investigator will be a pharmacist.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Rabeprazole Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00125736 ↗ A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium Completed Eisai Co., Ltd. Phase 4 2005-08-01 The purpose of this study is to investigate the efficacy and safety of combination use of E0671 and Rabeprazole Sodium in patients with gastric ulcer.
NCT00125736 ↗ A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium Completed Eisai Limited Phase 4 2005-08-01 The purpose of this study is to investigate the efficacy and safety of combination use of E0671 and Rabeprazole Sodium in patients with gastric ulcer.
NCT00132496 ↗ Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole Completed Eisai Inc. Phase 2 2005-08-01 The primary objective of this study is to collect safety information on rabeprazole 10 mg and 20 mg in the treatment of gastroesophageal reflux disease (GERD) in children aged 12 to 16 years. The secondary objectives are to assess the efficacy of rabeprazole on the improvement of the symptoms of GERD and to explore the relationship of symptom relief to dose received, based on symptom frequency and severity, antacid use, and quality of life (QOL) measures.
NCT00165646 ↗ A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease Completed Eisai Co., Ltd. Phase 3 2004-09-01 To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind, comparative study.
NCT00165672 ↗ A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease Completed Eisai Limited Phase 3 2005-05-01 To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).
NCT00165672 ↗ A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease Completed Eisai Inc. Phase 3 2005-05-01 To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).
NCT00216450 ↗ Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults. Completed Janssen Cilag Pharmaceutica S.A.C.I., Greece Phase 4 2004-10-01 The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of adult patients with Helicobacter pylori (H. pylori) infection in routine clinical practice.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rabeprazole Sodium

Condition Name

Condition Name for Rabeprazole Sodium
Intervention Trials
Healthy 10
Gastroesophageal Reflux 8
Gastroesophageal Reflux Disease (GERD) 5
Heartburn 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rabeprazole Sodium
Intervention Trials
Gastroesophageal Reflux 20
Esophagitis, Peptic 17
Esophagitis 4
Heartburn 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rabeprazole Sodium

Trials by Country

Trials by Country for Rabeprazole Sodium
Location Trials
United States 137
Japan 119
India 16
Germany 13
Argentina 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rabeprazole Sodium
Location Trials
California 7
Texas 6
Ohio 6
New York 6
Illinois 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rabeprazole Sodium

Clinical Trial Phase

Clinical Trial Phase for Rabeprazole Sodium
Clinical Trial Phase Trials
Phase 4 6
Phase 3 13
Phase 2 6
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rabeprazole Sodium
Clinical Trial Phase Trials
Completed 43
Not yet recruiting 3
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rabeprazole Sodium

Sponsor Name

Sponsor Name for Rabeprazole Sodium
Sponsor Trials
Eisai Inc. 14
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 6
Eisai Co., Ltd. 5
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rabeprazole Sodium
Sponsor Trials
Industry 51
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.